-
1
-
-
3142739323
-
Adrenergic targets for the treatment of cognitive deficits in schizophrenia
-
A.Arnsten (2004) Adrenergic targets for the treatment of cognitive deficits in schizophrenia. Psychopharmacology (Berl)174: 25–31.
-
(2004)
Psychopharmacology (Berl)
, vol.174
, pp. 25-31
-
-
Arnsten, A.1
-
3
-
-
0032007608
-
Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence
-
J.ArntT.Skarsfeldt (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology18: 63–101.
-
(1998)
Neuropsychopharmacology
, vol.18
, pp. 63-101
-
-
Arnt, J.1
Skarsfeldt, T.2
-
4
-
-
0034745153
-
The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?
-
R.BantickJ.DeakinP.Grasby (2001) The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?J Psychopharmacol15: 37–46.
-
(2001)
J Psychopharmacol
, vol.15
, pp. 37-46
-
-
Bantick, R.1
Deakin, J.2
Grasby, P.3
-
5
-
-
0024358369
-
A rating scale for drug-induced akathisia
-
T.Barnes (1989) A rating scale for drug-induced akathisia. Br J Psychiatry154: 672–676.
-
(1989)
Br J Psychiatry
, vol.154
, pp. 672-676
-
-
Barnes, T.1
-
6
-
-
29344438343
-
Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety
-
P.BlierS.Szabo (2005) Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J Clin Psychiatry66(Suppl. 8): 30–40.
-
(2005)
J Clin Psychiatry
, vol.66
, pp. 30-40
-
-
Blier, P.1
Szabo, S.2
-
8
-
-
84896715449
-
α2-adrenoceptors are targets for antipsychotic drugs
-
J.BrosdaF.JantschakH.Pertz (2014) α2-adrenoceptors are targets for antipsychotic drugs. Psychopharmacology231: 801–812.
-
(2014)
Psychopharmacology
, vol.231
, pp. 801-812
-
-
Brosda, J.1
Jantschak, F.2
Pertz, H.3
-
9
-
-
0036089687
-
Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors
-
K.BurrisT.MolskiC.XuE.RyanK.TottoriT.Kikuchi. (2002) Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther302: 381–389.
-
(2002)
J Pharmacol Exp Ther
, vol.302
, pp. 381-389
-
-
Burris, K.1
Molski, T.2
Xu, C.3
Ryan, E.4
Tottori, K.5
Kikuchi, T.6
-
10
-
-
10544243792
-
Side effect profiles of new antipsychotic agents
-
discussion 46–52
-
D.Casey (1996) Side effect profiles of new antipsychotic agents. J Clin Psychiatry57(Suppl. 11): 40–45, discussion 46–52.
-
(1996)
J Clin Psychiatry
, vol.57
, pp. 40-45
-
-
Casey, D.1
-
11
-
-
51849168937
-
Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study
-
D.CaseyE.SandsJ.HeisterbergH.Yang (2008) Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. Psychopharmacology (Berl)200: 317–331.
-
(2008)
Psychopharmacology (Berl)
, vol.200
, pp. 317-331
-
-
Casey, D.1
Sands, E.2
Heisterberg, J.3
Yang, H.4
-
12
-
-
84872473680
-
Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability
-
L.Citrome (2013) Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol9: 193–206.
-
(2013)
Expert Opin Drug Metab Toxicol
, vol.9
, pp. 193-206
-
-
Citrome, L.1
-
13
-
-
84940448621
-
Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
-
L.Citrome (2015) Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?Int J Clin Pract69: 978–997.
-
(2015)
Int J Clin Pract
, vol.69
, pp. 978-997
-
-
Citrome, L.1
-
14
-
-
77954166205
-
From receptor pharmacology to improved outcomes: individualizing the selection, dosing, and switching of antipsychotics
-
C.Correll (2010) From receptor pharmacology to improved outcomes: individualizing the selection, dosing, and switching of antipsychotics. Eur Psychiatry25(Suppl. 2): S12–S21.
-
(2010)
Eur Psychiatry
, vol.25
, pp. 12-21
-
-
Correll, C.1
-
15
-
-
84915755691
-
Cardio metabolic risk in first episode schizophrenia-spectrum disorder patients: baseline results from the RAISE-ETP study
-
C.CorrellD.RobinsonN.SchoolerM.BrunetteK.MueserR.Rosenheck. (2014) Cardio metabolic risk in first episode schizophrenia-spectrum disorder patients: baseline results from the RAISE-ETP study. JAMA Psychiatry71: 1350–1363.
-
(2014)
JAMA Psychiatry
, vol.71
, pp. 1350-1363
-
-
Correll, C.1
Robinson, D.2
Schooler, N.3
Brunette, M.4
Mueser, K.5
Rosenheck, R.6
-
16
-
-
84937234454
-
Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial
-
C.CorrellA.SkubanJ.OuyangM.HobartS.PfisterR.McQuade. (2015) Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial. Am J Psychiatry172: 870–880.
-
(2015)
Am J Psychiatry
, vol.172
, pp. 870-880
-
-
Correll, C.1
Skuban, A.2
Ouyang, J.3
Hobart, M.4
Pfister, S.5
McQuade, R.6
-
17
-
-
58149469090
-
Translational control of long lasting synaptic plasticity and memory
-
M.Costa-MattioliW.SossinE.KlannN.Sonenberg (2009) Translational control of long lasting synaptic plasticity and memory. Neuron61: 10–26.
-
(2009)
Neuron
, vol.61
, pp. 10-26
-
-
Costa-Mattioli, M.1
Sossin, W.2
Klann, E.3
Sonenberg, N.4
-
18
-
-
3142737856
-
The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia
-
J.CoyleG.Tsai (2004) The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology (Berl)174: 32–38.
-
(2004)
Psychopharmacology (Berl)
, vol.174
, pp. 32-38
-
-
Coyle, J.1
Tsai, G.2
-
19
-
-
62149121073
-
Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour
-
L.DahanH.HusumO.Mnie-FilaliJ.ArntP.HertelN.Haddjeri (2009) Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour. J Psychopharmacol23: 177–189.
-
(2009)
J Psychopharmacol
, vol.23
, pp. 177-189
-
-
Dahan, L.1
Husum, H.2
Mnie-Filali, O.3
Arnt, J.4
Hertel, P.5
Haddjeri, N.6
-
21
-
-
84903179140
-
Different effects of bifeprunox, aripiprazole, and haloperidol on body weight gain, food and water intake, and locomotor activity in rats
-
M.De SantisB.PanJ.LianX.HuangC.Deng (2014) Different effects of bifeprunox, aripiprazole, and haloperidol on body weight gain, food and water intake, and locomotor activity in rats. Pharmacol Biochem Behav124: 167–173.
-
(2014)
Pharmacol Biochem Behav
, vol.124
, pp. 167-173
-
-
De Santis, M.1
Pan, B.2
Lian, J.3
Huang, X.4
Deng, C.5
-
22
-
-
0036550282
-
Alpha1b-adrenergic receptors control locomotor and rewarding effects of psychostimulants and opiates
-
C.DrouinL.DarracqF.TroveroG.BlancJ.GlowinskiS.Cotecchia. (2002) Alpha1b-adrenergic receptors control locomotor and rewarding effects of psychostimulants and opiates. J Neurosci22: 2873–2884.
-
(2002)
J Neurosci
, vol.22
, pp. 2873-2884
-
-
Drouin, C.1
Darracq, L.2
Trovero, F.3
Blanc, G.4
Glowinski, J.5
Cotecchia, S.6
-
23
-
-
84862156355
-
Initial validity and reliability data on the Columbia-Suicide Severity Rating Scale
-
author reply 663
-
P.ChappellD.FeltnerC.MakumiM.Stewart (2012) Initial validity and reliability data on the Columbia-Suicide Severity Rating Scale. Am J Psychiatry169: 662–663; author reply 663.
-
(2012)
Am J Psychiatry
, vol.169
, pp. 662-663
-
-
Chappell, P.1
Feltner, D.2
Makumi, C.3
Stewart, M.4
-
25
-
-
0032414602
-
Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression
-
J.FawcettR.Barkin (1998) Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord51: 267–285.
-
(1998)
J Affect Disord
, vol.51
, pp. 267-285
-
-
Fawcett, J.1
Barkin, R.2
-
27
-
-
0142244688
-
Schizophrenia
-
R.Freedman (2003) Schizophrenia. N Engl J Med349: 1738–1749.
-
(2003)
N Engl J Med
, vol.349
, pp. 1738-1749
-
-
Freedman, R.1
-
28
-
-
37349093431
-
The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long acting injectable
-
G.GharabawiC.BossieI.TurkozM.KujawaR.MahmoudG.Simpson (2007) The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long acting injectable. J Nerv Ment Dis195: 976–982.
-
(2007)
J Nerv Ment Dis
, vol.195
, pp. 976-982
-
-
Gharabawi, G.1
Bossie, C.2
Turkoz, I.3
Kujawa, M.4
Mahmoud, R.5
Simpson, G.6
-
29
-
-
84941126254
-
Brexpiprazole: a new antipsychotic following in the footsteps of aripiprazole
-
D.Goff (2015) Brexpiprazole: a new antipsychotic following in the footsteps of aripiprazole. Am J Psychiatry172: 820–821.
-
(2015)
Am J Psychiatry
, vol.172
, pp. 820-821
-
-
Goff, D.1
-
30
-
-
0029918481
-
What are the functional consequences of neurocognitive deficits in schizophrenia?
-
M.Green (1996) What are the functional consequences of neurocognitive deficits in schizophrenia?Am J Psychiatry153: 321–330.
-
(1996)
Am J Psychiatry
, vol.153
, pp. 321-330
-
-
Green, M.1
-
31
-
-
4444220908
-
Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria
-
M.GreenK.NuechterleinJ.GoldD.BarchJ.CohenS.Essock. (2004) Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry56: 301–307.
-
(2004)
Biol Psychiatry
, vol.56
, pp. 301-307
-
-
Green, M.1
Nuechterlein, K.2
Gold, J.3
Barch, D.4
Cohen, J.5
Essock, S.6
-
32
-
-
84868311517
-
The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions
-
G.GrossK.Drescher (2012) The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions. Handb Exp Pharmacol213: 167–210.
-
(2012)
Handb Exp Pharmacol
, vol.213
, pp. 167-210
-
-
Gross, G.1
Drescher, K.2
-
33
-
-
0003412410
-
-
Rockville, MD: National Institute of Mental Health,, (ed) (,. US Department of Health, Education and Welfare Publication (ADM)
-
W.Guy (ed) (1976) ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education and Welfare Publication (ADM) 76–338. Rockville, MD: National Institute of Mental Health.
-
(1976)
ECDEU Assessment Manual for Psychopharmacology
, pp. 76-338
-
-
Guy, W.1
-
34
-
-
0030431697
-
Effect of the alpha-2 adrenoceptor antagonist mirtazapine on the 5-hydroxytryptamine system in the rat brain
-
N.HaddjeriP.BlierC.de Montigny (1996) Effect of the alpha-2 adrenoceptor antagonist mirtazapine on the 5-hydroxytryptamine system in the rat brain. J Pharmacol Exp Ther277: 861–871.
-
(1996)
J Pharmacol Exp Ther
, vol.277
, pp. 861-871
-
-
Haddjeri, N.1
Blier, P.2
de Montigny, C.3
-
35
-
-
42749092601
-
Phencyclidine induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT1A receptor
-
H.HagiwaraY.FujitaT.IshimaS.KunitachiY.ShirayamaM.Iyo. (2008) Phencyclidine induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT1A receptor. Eur Neuropsychopharmacol18: 448–454.
-
(2008)
Eur Neuropsychopharmacol
, vol.18
, pp. 448-454
-
-
Hagiwara, H.1
Fujita, Y.2
Ishima, T.3
Kunitachi, S.4
Shirayama, Y.5
Iyo, M.6
-
36
-
-
33748455912
-
The NMDA receptor hypofunction hypothesis for schizophrenia and glycine modulatory sites on the NMDA receptors as potential therapeutic drugs
-
K.Hashimoto (2006) The NMDA receptor hypofunction hypothesis for schizophrenia and glycine modulatory sites on the NMDA receptors as potential therapeutic drugs. Clin Psychopharmacol Neurosci4: 3–10.
-
(2006)
Clin Psychopharmacol Neurosci
, vol.4
, pp. 3-10
-
-
Hashimoto, K.1
-
37
-
-
84906228003
-
Targeting of NMDA receptors in new treatments for schizophrenia
-
K.Hashimoto (2014) Targeting of NMDA receptors in new treatments for schizophrenia. Expert Opin Ther Targets18: 1049–1063.
-
(2014)
Expert Opin Ther Targets
, vol.18
, pp. 1049-1063
-
-
Hashimoto, K.1
-
38
-
-
27744572308
-
Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol
-
K.HashimotoY.FujitaE.ShimizuM.Iyo (2005) Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol. Eur J Pharmacol519: 114–117.
-
(2005)
Eur J Pharmacol
, vol.519
, pp. 114-117
-
-
Hashimoto, K.1
Fujita, Y.2
Shimizu, E.3
Iyo, M.4
-
39
-
-
78149472832
-
A novel target of action of minocycline in NGF-induced neurite outgrowth in PC12 cells: translation initiation factor eIF4AI
-
K.HashimotoT.Ishima (2010) A novel target of action of minocycline in NGF-induced neurite outgrowth in PC12 cells: translation initiation factor eIF4AI. PLoS ONE5: e15430.
-
(2010)
PLoS ONE
, vol.5
, pp. 15430
-
-
Hashimoto, K.1
Ishima, T.2
-
40
-
-
79952285928
-
Neurite outgrowth mediated by translation elongation factor eEF1A1: a target for antiplatelet agent cilostazol
-
K.HashimotoT.Ishima (2011) Neurite outgrowth mediated by translation elongation factor eEF1A1: a target for antiplatelet agent cilostazol. PLoS One6: e17431.
-
(2011)
PLoS One
, vol.6
, pp. 17431
-
-
Hashimoto, K.1
Ishima, T.2
-
42
-
-
84937714818
-
Brexpiprazole: another multipurpose antipsychotic drug?
-
R.Howland (2015) Brexpiprazole: another multipurpose antipsychotic drug?J Psychosoc Nurs Ment Health Serv53: 23–25.
-
(2015)
J Psychosoc Nurs Ment Health Serv
, vol.53
, pp. 23-25
-
-
Howland, R.1
-
43
-
-
0037239089
-
Extra pyramidal symptom profiles assessed with the Drug-Induced Extra pyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol
-
T.InadaC.BeasleyY.TanakaD.Walker (2003) Extra pyramidal symptom profiles assessed with the Drug-Induced Extra pyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol. Int Clin Psychopharmacol18: 39–48.
-
(2003)
Int Clin Psychopharmacol
, vol.18
, pp. 39-48
-
-
Inada, T.1
Beasley, C.2
Tanaka, Y.3
Walker, D.4
-
44
-
-
84928212338
-
Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin–dopamine activity modulator: a role for serotonin 5-HT1A and 5-HT2A receptors
-
T.IshimaT.FutamuraY.OhgiN.YoshimiT.KikuchiK.Hashimoto (2015) Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin–dopamine activity modulator: a role for serotonin 5-HT1A and 5-HT2A receptors. Eur Neuropsychopharm25: 505–511.
-
(2015)
Eur Neuropsychopharm
, vol.25
, pp. 505-511
-
-
Ishima, T.1
Futamura, T.2
Ohgi, Y.3
Yoshimi, N.4
Kikuchi, T.5
Hashimoto, K.6
-
45
-
-
84861369885
-
Potentiation of nerve growth factor induced neurite outgrowth in PC 12 cells by ifenprodil: role of sigma-1and IP3 receptors
-
T.IshimaK.Hashimoto (2012) Potentiation of nerve growth factor induced neurite outgrowth in PC 12 cells by ifenprodil: role of sigma-1and IP3 receptors. PLoS ONE7: e37989.
-
(2012)
PLoS ONE
, vol.7
, pp. 37989
-
-
Ishima, T.1
Hashimoto, K.2
-
46
-
-
84873941807
-
Neurite outgrowth mediated by the heat shock protein HSP90α: a novel target for the antipsychotic drug aripiprazole
-
T.IshimaM.IyoK.Hashimoto (2012) Neurite outgrowth mediated by the heat shock protein HSP90α: a novel target for the antipsychotic drug aripiprazole. Transl Psychiatry2: e170.
-
(2012)
Transl Psychiatry
, vol.2
, pp. 170
-
-
Ishima, T.1
Iyo, M.2
Hashimoto, K.3
-
47
-
-
79951553138
-
Potentiation of NGF-induced neurite outgrowth in PC12 cells by papaverine: role played by PLC-gamma and IP3 receptors
-
K.ItohT.IshimaJ.KehlerK.Hashimoto (2011) Potentiation of NGF-induced neurite outgrowth in PC12 cells by papaverine: role played by PLC-gamma and IP3 receptors. Brain Res1377: 32–40.
-
(2011)
Brain Res
, vol.1377
, pp. 32-40
-
-
Itoh, K.1
Ishima, T.2
Kehler, J.3
Hashimoto, K.4
-
48
-
-
84928640856
-
A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia
-
J.KaneA.SkubanJ.OuyangM.HobartS.PfisterR.McQuade. (2015) A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizphr Res164: 127–135.
-
(2015)
Schizphr Res
, vol.164
, pp. 127-135
-
-
Kane, J.1
Skuban, A.2
Ouyang, J.3
Hobart, M.4
Pfister, S.5
McQuade, R.6
-
50
-
-
0029023002
-
7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity
-
T.KikuchiK.TottoriY.UwahodoT.HiroseT.MiwaY.Oshiro. (1995) 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther274: 329–336.
-
(1995)
J Pharmacol Exp Ther
, vol.274
, pp. 329-336
-
-
Kikuchi, T.1
Tottori, K.2
Uwahodo, Y.3
Hirose, T.4
Miwa, T.5
Oshiro, Y.6
-
51
-
-
77949701274
-
Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist partial agonist antipsychotic candidate: in vitro and neurochemical profile
-
B.KissA.HorváthZ.NémethyE.SchmidtI.LaszlovszkyG.Bugovics. (2010) Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther333: 328–340.
-
(2010)
J Pharmacol Exp Ther
, vol.333
, pp. 328-340
-
-
Kiss, B.1
Horváth, A.2
Némethy, Z.3
Schmidt, E.4
Laszlovszky, I.5
Bugovics, G.6
-
52
-
-
0030440884
-
Differential effects of direct and indirect dopamine agonists on eye blink rate in cynomolgus monkeys
-
M.KlevenW.Koek (1996) Differential effects of direct and indirect dopamine agonists on eye blink rate in cynomolgus monkeys. J Pharmacol Exp Ther279: 1211–1219.
-
(1996)
J Pharmacol Exp Ther
, vol.279
, pp. 1211-1219
-
-
Kleven, M.1
Koek, W.2
-
54
-
-
50349086333
-
Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis
-
T.KurokiN.NagaoT.Nakahara (2008) Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. Prog Brain Res172: 199–212.
-
(2008)
Prog Brain Res
, vol.172
, pp. 199-212
-
-
Kuroki, T.1
Nagao, N.2
Nakahara, T.3
-
55
-
-
84922079754
-
Antipsychotic induced elevation of creatine kinase: a systematic review of the literature and recommendations for the clinical practice
-
Z.LaoutidisK.Kioulos (2014) Antipsychotic induced elevation of creatine kinase: a systematic review of the literature and recommendations for the clinical practice. Psychopharmacology (Berl)231: 4255–4270.
-
(2014)
Psychopharmacology (Berl)
, vol.231
, pp. 4255-4270
-
-
Laoutidis, Z.1
Kioulos, K.2
-
56
-
-
84898057496
-
5-HT2A receptor antagonists for the treatment of neuroleptic-induced akathisia: a systematic review and meta-analysis
-
Z.LaoutidisC.Luckhaus (2014) 5-HT2A receptor antagonists for the treatment of neuroleptic-induced akathisia: a systematic review and meta-analysis. Int J Neuropsychopharmacol17: 823–832.
-
(2014)
Int J Neuropsychopharmacol
, vol.17
, pp. 823-832
-
-
Laoutidis, Z.1
Luckhaus, C.2
-
57
-
-
84884161208
-
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple treatments meta-analysis
-
S.LeuchtA.CiprianiL.SpineliD.MavridisD.OreyF.Richter (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple treatments meta-analysis. Lancet382: 951–962.
-
(2013)
Lancet
, vol.382
, pp. 951-962
-
-
Leucht, S.1
Cipriani, A.2
Spineli, L.3
Mavridis, D.4
Orey, D.5
Richter, F.6
-
58
-
-
0035666578
-
The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches
-
J.LiebermanD.PerkinsA.BelgerM.ChakosF.JarskogK.Boteva. (2001) The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry50: 884–897.
-
(2001)
Biol Psychiatry
, vol.50
, pp. 884-897
-
-
Lieberman, J.1
Perkins, D.2
Belger, A.3
Chakos, M.4
Jarskog, F.5
Boteva, K.6
-
60
-
-
84904981694
-
Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator
-
K.MaedaL.LerdrupH.SuginoH.AkazawaN.AmadaR.McQuade. (2014a) Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther350: 605–614.
-
(2014)
J Pharmacol Exp Ther
, vol.350
, pp. 605-614
-
-
Maeda, K.1
Lerdrup, L.2
Sugino, H.3
Akazawa, H.4
Amada, N.5
McQuade, R.6
-
61
-
-
84903982078
-
Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator
-
K.MaedaH.SuginoH.AkazawaN.AmadaJ.ShimadaT.Futamura. (2014b) Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther350: 589–604.
-
(2014)
J Pharmacol Exp Ther
, vol.350
, pp. 589-604
-
-
Maeda, K.1
Sugino, H.2
Akazawa, H.3
Amada, N.4
Shimada, J.5
Futamura, T.6
-
62
-
-
34648830603
-
Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study
-
D.MamoA.GraffR.MizrahiC.ShammiF.RomeyerS.Kapur (2007) Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry164: 1411–1417.
-
(2007)
Am J Psychiatry
, vol.164
, pp. 1411-1417
-
-
Mamo, D.1
Graff, A.2
Mizrahi, R.3
Shammi, C.4
Romeyer, F.5
Kapur, S.6
-
63
-
-
77957241598
-
Adjunctive alpha2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission
-
M.MarcusC.WikerO.FrånbergA.Konradsson-GeukenX.LangloisK.Jardemark. (2010) Adjunctive alpha2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission. Int J Neuropsychopharmacol13: 891–903.
-
(2010)
Int J Neuropsychopharmacol
, vol.13
, pp. 891-903
-
-
Marcus, M.1
Wiker, C.2
Frånberg, O.3
Konradsson-Geuken, A.4
Langlois, X.5
Jardemark, K.6
-
64
-
-
0031431410
-
The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials
-
S.MarderJ.DavisG.Chouinard (1997) The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry58: 538–546.
-
(1997)
J Clin Psychiatry
, vol.58
, pp. 538-546
-
-
Marder, S.1
Davis, J.2
Chouinard, G.3
-
65
-
-
33747308393
-
Serum creatine kinase levels in chronic psychosis patients: a comparison between atypical and conventional antipsychotics
-
K.Melkersson (2006) Serum creatine kinase levels in chronic psychosis patients: a comparison between atypical and conventional antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry30: 1277–1282.
-
(2006)
Prog Neuropsychopharmacol Biol Psychiatry
, vol.30
, pp. 1277-1282
-
-
Melkersson, K.1
-
66
-
-
0032868798
-
The role of serotonin in antipsychotic drug action
-
H.Meltzer (1999) The role of serotonin in antipsychotic drug action. Neuropsychopharmacology21(2 Suppl.): 106S–115S.
-
(1999)
Neuropsychopharmacology
, vol.21
, Issue.2
, pp. 106-115
-
-
Meltzer, H.1
-
67
-
-
84868332431
-
Serotonergic mechanisms as targets for existing and novel antipsychotics
-
H.Meltzer (2012) Serotonergic mechanisms as targets for existing and novel antipsychotics. Handb Exp Pharmacol212: 87–124.
-
(2012)
Handb Exp Pharmacol
, vol.212
, pp. 87-124
-
-
Meltzer, H.1
-
68
-
-
77957751075
-
Potentiation of nerve growth factor induced neurite out growth by the ROCK inhibitor Y-27632: a possible role of IP3 receptors
-
T.MinaseT.IshimaK.ItohK.Hashimoto (2010) Potentiation of nerve growth factor induced neurite out growth by the ROCK inhibitor Y-27632: a possible role of IP3 receptors. Eur J Pharmacol648: 67–73.
-
(2010)
Eur J Pharmacol
, vol.648
, pp. 67-73
-
-
Minase, T.1
Ishima, T.2
Itoh, K.3
Hashimoto, K.4
-
69
-
-
0027446907
-
In vivo electrophysiological evidence for tonic activation by endogenous noradrenaline of alpha 2-adrenergic receptors on 5-hydroxytryptamine terminals in the rat hippo campus
-
R.MongeauP.BlierC.deMontigny (1993) In vivo electrophysiological evidence for tonic activation by endogenous noradrenaline of alpha 2-adrenergic receptors on 5-hydroxytryptamine terminals in the rat hippo campus. Naunyn Schmiedebergs Arch Pharmacol347: 266–272.
-
(1993)
Naunyn Schmiedebergs Arch Pharmacol
, vol.347
, pp. 266-272
-
-
Mongeau, R.1
Blier, P.2
deMontigny, C.3
-
70
-
-
77954120696
-
Serotonin 5-HT(2A) receptor antagonists in the treatment of insomnia: present status and future prospects
-
J.Monti (2010) Serotonin 5-HT(2A) receptor antagonists in the treatment of insomnia: present status and future prospects. Drugs Today (Barc)46: 183–193.
-
(2010)
Drugs Today (Barc)
, vol.46
, pp. 183-193
-
-
Monti, J.1
-
71
-
-
79953100409
-
Validation of the excited component of the Positive and Negative Syndrome Scale (PANSSEC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room
-
A.MontoyaA.ValladaresL.LizánL.SanR.EscobarS.Paz (2011) Validation of the excited component of the Positive and Negative Syndrome Scale (PANSSEC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room. Health Qual Life Outcomes9: 18.
-
(2011)
Health Qual Life Outcomes
, vol.9
, pp. 18
-
-
Montoya, A.1
Valladares, A.2
Lizán, L.3
San, L.4
Escobar, R.5
Paz, S.6
-
72
-
-
69049088714
-
Effect of sertindole on extracellular dopamine and glutamate in the frontal cortex of conscious rats: a comparison with risperidone and exploration of mechanisms involved
-
A.MørkL.WittenJ.Arnt (2009) Effect of sertindole on extracellular dopamine and glutamate in the frontal cortex of conscious rats: a comparison with risperidone and exploration of mechanisms involved. Eur J Pharmacol206: 39–49.
-
(2009)
Eur J Pharmacol
, vol.206
, pp. 39-49
-
-
Mørk, A.1
Witten, L.2
Arnt, J.3
-
73
-
-
0034022621
-
Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning
-
P.MorosiniL.MaglianoL.BrambillaS.UgoliniR.Pioli (2000) Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand101: 323–329.
-
(2000)
Acta Psychiatr Scand
, vol.101
, pp. 323-329
-
-
Morosini, P.1
Magliano, L.2
Brambilla, L.3
Ugolini, S.4
Pioli, R.5
-
74
-
-
0033395494
-
Latent structures underlying schizophrenic symptoms: a five-dimensional model
-
M.NakayaH.SuwaK.Ohmori (1999) Latent structures underlying schizophrenic symptoms: a five-dimensional model. Schizophr Res39: 39–50.
-
(1999)
Schizophr Res
, vol.39
, pp. 39-50
-
-
Nakaya, M.1
Suwa, H.2
Ohmori, K.3
-
75
-
-
69949087539
-
Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials
-
J.NelsonG.Papakostas (2009) Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry166: 980–991.
-
(2009)
Am J Psychiatry
, vol.166
, pp. 980-991
-
-
Nelson, J.1
Papakostas, G.2
-
76
-
-
34347336444
-
Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third generation antipsychotics
-
A.Newman-TancrediD.CussacR.Depoortere (2007) Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third generation antipsychotics. Curr Opin Investig Drugs8: 539–554.
-
(2007)
Curr Opin Investig Drugs
, vol.8
, pp. 539-554
-
-
Newman-Tancredi, A.1
Cussac, D.2
Depoortere, R.3
-
77
-
-
79961166634
-
Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties
-
A.Newman-TancrediM.Kleven (2011) Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. Psychopharmacology (Berl)216: 451–473.
-
(2011)
Psychopharmacology (Berl)
, vol.216
, pp. 451-473
-
-
Newman-Tancredi, A.1
Kleven, M.2
-
78
-
-
84857134134
-
Sigma-1 receptor agonists as therapeutic drugs for cognitive impairments in neuropsychiatric disease
-
T.NiitsuM.IyoK.Hashimoo (2012) Sigma-1 receptor agonists as therapeutic drugs for cognitive impairments in neuropsychiatric disease. Curr Pharm Des18: 875–883.
-
(2012)
Curr Pharm Des
, vol.18
, pp. 875-883
-
-
Niitsu, T.1
Iyo, M.2
Hashimoo, K.3
-
79
-
-
49749117054
-
Potentiation of nerve growth factor induced neurite outgrowth by fluvoxamine: role of sigma-1receptors, IP3 receptors and cellular signaling pathways
-
T.NishimuraT.IshimaM.IyoK.Hashimoto (2008) Potentiation of nerve growth factor induced neurite outgrowth by fluvoxamine: role of sigma-1receptors, IP3 receptors and cellular signaling pathways. PLoS ONE3: e2558.
-
(2008)
PLoS ONE
, vol.3
, pp. 2558
-
-
Nishimura, T.1
Ishima, T.2
Iyo, M.3
Hashimoto, K.4
-
81
-
-
84908428543
-
Acute effects of brexpiprazole on serotonin, dopamine, and norepinephrine systems: an in vivo electrophysiologic characterization
-
C.OosterhofM.MansariP.Blier (2014) Acute effects of brexpiprazole on serotonin, dopamine, and norepinephrine systems: an in vivo electrophysiologic characterization. J Pharmacol Exp Ther351: 585–595.
-
(2014)
J Pharmacol Exp Ther
, vol.351
, pp. 585-595
-
-
Oosterhof, C.1
Mansari, M.2
Blier, P.3
-
82
-
-
84863393105
-
The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults
-
K.PosnerG.BrownB.StanleyD.BrentK.YershovaM.Oquendo (2011) The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry168: 1266–1277.
-
(2011)
Am J Psychiatry
, vol.168
, pp. 1266-1277
-
-
Posner, K.1
Brown, G.2
Stanley, B.3
Brent, D.4
Yershova, K.5
Oquendo, M.6
-
83
-
-
84884489165
-
Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole
-
S.PotkinA.RaoufiniaS.MallikaarjunP.BricmontT.Peters-StricklandW.Kasper. (2013) Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole. Curr Med Res Opin29: 1241–1251.
-
(2013)
Curr Med Res Opin
, vol.29
, pp. 1241-1251
-
-
Potkin, S.1
Raoufinia, A.2
Mallikaarjun, S.3
Bricmont, P.4
Peters-Strickland, T.5
Kasper, W.6
-
84
-
-
4644271084
-
Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia
-
B.RothD.ShefflerW.Kroeze (2004) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov3: 353–359.
-
(2004)
Nat Rev Drug Discov
, vol.3
, pp. 353-359
-
-
Roth, B.1
Sheffler, D.2
Kroeze, W.3
-
85
-
-
84555186903
-
Second-generation antipsychotic drugs and extra pyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons
-
C.Rummel-KlugeK.KomossaS.SchwarzH.HungerF.SchmidW.Kissling. (2012) Second-generation antipsychotic drugs and extra pyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull38: 167–177.
-
(2012)
Schizophr Bull
, vol.38
, pp. 167-177
-
-
Rummel-Kluge, C.1
Komossa, K.2
Schwarz, S.3
Hunger, H.4
Schmid, F.5
Kissling, W.6
-
86
-
-
84883815411
-
Pharmacological characterization of a structurally novel a2C-adrenoceptor antagonist ORM-10921 and its effects in neuropsychiatric models
-
J.SallinenJ.HolappaA.KoivistoK.KuokkanenH.ChapmanJ.Lehtimäki. (2013) Pharmacological characterization of a structurally novel a2C-adrenoceptor antagonist ORM-10921 and its effects in neuropsychiatric models. Basic Clin Pharmacol Toxicol113: 239–249.
-
(2013)
Basic Clin Pharmacol Toxicol
, vol.113
, pp. 239-249
-
-
Sallinen, J.1
Holappa, J.2
Koivisto, A.3
Kuokkanen, K.4
Chapman, H.5
Lehtimäki, J.6
-
87
-
-
0014723449
-
A rating scale for extra pyramidal side effects
-
G.SimpsonJ.Angus (1970) A rating scale for extra pyramidal side effects. Acta Psychiatr Scand Suppl212: 11–19.
-
(1970)
Acta Psychiatr Scand Suppl
, vol.212
, pp. 11-19
-
-
Simpson, G.1
Angus, J.2
-
88
-
-
76749163673
-
Attenuation of phencyclidine induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine (2A) receptor inverse agonist
-
S.SnigdhaM.HoriguchiM.HuangZ.LiM.ShahidJ.Neill. (2010) Attenuation of phencyclidine induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine (2A) receptor inverse agonist. J Pharmacol Exp Ther332: 622–631.
-
(2010)
J Pharmacol Exp Ther
, vol.332
, pp. 622-631
-
-
Snigdha, S.1
Horiguchi, M.2
Huang, M.3
Li, Z.4
Shahid, M.5
Neill, J.6
-
89
-
-
0027887319
-
Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors
-
C.StockmeierJ.DiCarloY.ZhangP.ThompsonH.Meltzer (1993) Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. J Pharmacol Exp Ther266: 1374–1384.
-
(1993)
J Pharmacol Exp Ther
, vol.266
, pp. 1374-1384
-
-
Stockmeier, C.1
DiCarlo, J.2
Zhang, Y.3
Thompson, P.4
Meltzer, H.5
-
90
-
-
0034810016
-
Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment
-
T.SumiyoshiM.MatsuiS.NoharaI.YamashitaM.KurachiC.Sumiyoshi. (2001a) Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry158: 1722–1725.
-
(2001)
Am J Psychiatry
, vol.158
, pp. 1722-1725
-
-
Sumiyoshi, T.1
Matsui, M.2
Nohara, S.3
Yamashita, I.4
Kurachi, M.5
Sumiyoshi, C.6
-
91
-
-
0035873389
-
The effect of tandospirone, a serotonin-1A agonist, on memory function in schizophrenia
-
T.SumiyoshiM.MatsuiI.YamashitaS.NoharaM.KurachiT.Uehara. (2001b) The effect of tandospirone, a serotonin-1A agonist, on memory function in schizophrenia. Biol Psychiatry49: 861–868.
-
(2001)
Biol Psychiatry
, vol.49
, pp. 861-868
-
-
Sumiyoshi, T.1
Matsui, M.2
Yamashita, I.3
Nohara, S.4
Kurachi, M.5
Uehara, T.6
-
92
-
-
84938735906
-
Efficacy and safety of adjunctive brexpiprazole (OPC-34712) in major depressive disorder: results of two pivotal clinical studies
-
M.ThaseJ.YouakimA.SkubanM.HobartP.ZhangS.Legacy. (2014). Efficacy and safety of adjunctive brexpiprazole (OPC-34712) in major depressive disorder: results of two pivotal clinical studies. Neuropsychopharmacology39: S357.
-
(2014)
Neuropsychopharmacology
, vol.39
, pp. 357
-
-
Thase, M.1
Youakim, J.2
Skuban, A.3
Hobart, M.4
Zhang, P.5
Legacy, S.6
-
93
-
-
84942502416
-
Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants
-
M.ThaseJ.YouakimA.SkubanM.HobartC.AugustineP.Zhang. (2015a) Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry76: 1224–1231.
-
(2015)
J Clin Psychiatry
, vol.76
, pp. 1224-1231
-
-
Thase, M.1
Youakim, J.2
Skuban, A.3
Hobart, M.4
Augustine, C.5
Zhang, P.6
-
94
-
-
84942502726
-
Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study
-
M.ThaseJ.YouakimA.SkubanM.HobartP.ZhangR.McQuade. (2015b) Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry76: 1232–1240.
-
(2015)
J Clin Psychiatry
, vol.76
, pp. 1232-1240
-
-
Thase, M.1
Youakim, J.2
Skuban, A.3
Hobart, M.4
Zhang, P.5
McQuade, R.6
-
95
-
-
85174274604
-
-
accessed 2 October 2015,,. :
-
US FDA (2015) Drugs. Available at: http://www.fda.gov/Drugs/default.htm (accessed 2 October 2015).
-
(2015)
Drugs
-
-
-
97
-
-
33745355536
-
The five-factor model of the Positive and Negative Syndrome Scale II: a ten-fold cross-validation of a revised model
-
M.Van der GaagT.HoffmanM.RemijsenR.HijmanL.de HaanB.van Meijel. (2006) The five-factor model of the Positive and Negative Syndrome Scale II: a ten-fold cross-validation of a revised model. Schizophr Res85: 280–287.
-
(2006)
Schizophr Res
, vol.85
, pp. 280-287
-
-
Van der Gaag, M.1
Hoffman, T.2
Remijsen, M.3
Hijman, R.4
de Haan, L.5
van Meijel, B.6
-
98
-
-
0142226998
-
Transient behavioral sensitization to nicotine becomes long-lasting with monoamine oxidases inhibitors
-
A.VillegierG.BlancJ.GlowinskiJ.Tassin (2003) Transient behavioral sensitization to nicotine becomes long-lasting with monoamine oxidases inhibitors. Pharmacol Biochem Behav76: 267–274.
-
(2003)
Pharmacol Biochem Behav
, vol.76
, pp. 267-274
-
-
Villegier, A.1
Blanc, G.2
Glowinski, J.3
Tassin, J.4
-
99
-
-
0028945429
-
Principal components and further possibilities with the PANSS
-
L.Von KnorringE.Lindstrom (1995) Principal components and further possibilities with the PANSS. Acta Psychiatr Scand Suppl388: 5–10.
-
(1995)
Acta Psychiatr Scand Suppl
, vol.388
, pp. 5-10
-
-
Von Knorring, L.1
Lindstrom, E.2
-
100
-
-
38049040370
-
Multi and single-target agents for major psychiatric diseases: therapeutic opportunities and challenges
-
E.WongS.NikamM.Shahid (2008) Multi and single-target agents for major psychiatric diseases: therapeutic opportunities and challenges. Curr Opin Investig Drugs9: 28–36.
-
(2008)
Curr Opin Investig Drugs
, vol.9
, pp. 28-36
-
-
Wong, E.1
Nikam, S.2
Shahid, M.3
-
101
-
-
0035983682
-
Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C] raclopride
-
F.YokoiG.GründerK.BiziereM.StephaneA.DoganR.Dannals. (2002) Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C] raclopride. Neuropsychopharmacology27: 248–259.
-
(2002)
Neuropsychopharmacology
, vol.27
, pp. 248-259
-
-
Yokoi, F.1
Gründer, G.2
Biziere, K.3
Stephane, M.4
Dogan, A.5
Dannals, R.6
-
102
-
-
84903988963
-
Effects of brexpiprazole, a novel serotonin–dopamine activity modulator, on phencyclidine induced cognitive deficits in mice: a role for serotonin5-HT1A receptors
-
N.YoshimiY.FujitaY.OhgiT.FutamuraT.KikuchiK.Hashimoto (2014) Effects of brexpiprazole, a novel serotonin–dopamine activity modulator, on phencyclidine induced cognitive deficits in mice: a role for serotonin5-HT1A receptors. Pharmacol Biochem Behav124: 245–249.
-
(2014)
Pharmacol Biochem Behav
, vol.124
, pp. 245-249
-
-
Yoshimi, N.1
Fujita, Y.2
Ohgi, Y.3
Futamura, T.4
Kikuchi, T.5
Hashimoto, K.6
-
103
-
-
84925944263
-
Improvement of dizocilpine induced social recognition deficits in mice by brexpiprazole, a novel serotonin–dopamine activity modulator
-
N.YoshimiT.FutamuraK.Hashimoto (2015) Improvement of dizocilpine induced social recognition deficits in mice by brexpiprazole, a novel serotonin–dopamine activity modulator. Eur Neuropsychopharm25: 356–364.
-
(2015)
Eur Neuropsychopharm
, vol.25
, pp. 356-364
-
-
Yoshimi, N.1
Futamura, T.2
Hashimoto, K.3
|